NTRK2全稱為神經(jīng)營養(yǎng)酪氨酸激酶受體2型（Neurotrophic Tyrosine Kinase Receptor Type 2），常簡稱為TrkB或GP145-TrkB。NTRK2是腦源性神經(jīng)營養(yǎng)因子（BDNF）的主要受體，通過與配體結(jié)合激活下游信號網(wǎng)絡(luò)，調(diào)控神經(jīng)元存活、突觸可塑性和神經(jīng)遞質(zhì)釋放，對學(xué)習(xí)記憶、情緒調(diào)節(jié)等腦功能至關(guān)重要。NTRK2信號異常與阿爾茨海默病、抑郁癥、癲癇等神經(jīng)系統(tǒng)疾病密切相關(guān)，其過度激活也可能導(dǎo)致神經(jīng)母細(xì)胞瘤、肺癌等實(shí)體瘤的發(fā)生。近年來針對NTRK基因家族融合突變的靶向治療取得突破，拉羅替尼（Larotrectinib）和恩曲替尼（Entrectinib）等泛TRK抑制劑已獲批用于NTRK融合陽性的實(shí)體瘤患者，但部分患者用藥后出現(xiàn)的激酶區(qū)耐藥突變?nèi)允桥R床挑戰(zhàn)。目前第二代TRK抑制劑如Selitrectinib正在研發(fā)中，旨在克服獲得性耐藥問題。

熱銷產(chǎn)品

NTRK2 Recombinant Monoclonal Antibody (CSB-RA619082MA1HU)

驗(yàn)證數(shù)據(jù)

Immunofluorescence staining of SH-SY5Y cell with CSB-RA619082MA1HU at 1:30, counter-stained with DAPI. The cells were fixed in 4% formaldehyde and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4C. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Mouse IgG(H+L).